WT1脉冲树突状细胞疫苗联合化疗用于切除性胰腺癌的I期研究

WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.

作者信息

Yanagisawa Ryu, Koizumi Tomonobu, Koya Terutsugu, Sano Kenji, Koido Shigeo, Nagai Kazuhiro, Kobayashi Masanori, Okamoto Masato, Sugiyama Haruo, Shimodaira Shigetaka

机构信息

Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan

Shinshu Cancer Center, Shinshu University Hospital, Matsumoto, Japan.

出版信息

Anticancer Res. 2018 Apr;38(4):2217-2225. doi: 10.21873/anticanres.12464.

DOI:10.21873/anticanres.12464

PMID:29599342

Abstract

BACKGROUND/AIM: Wilms' tumor 1 (WT1) is a tumor-associated antigen highly expressed in cancer. We examined the safety of WT1-peptide pulsed dendritic cell (WT1-DC) vaccine in combination with chemotherapy in patients with surgically resected pancreatic cancer.

PATIENTS AND METHODS

Eight patients with resectable pancreatic cancer undergoing surgery either combined with S-1 or S-1 plus gemcitabine therapy were enrolled. Immunohistochemical analysis of WT1 was performed in 34 cases of pancreatic cancer.

RESULTS

No serious side-effects were observed, except grade I fever in five and grade I reactions at the injection site in all patients. WT1-specific cytotoxic T-lymphocytes were detected in seven patients, and WT1 and human leukocyte antigen class I antigens were positive in all 34 cases.

CONCLUSION

Our study clarified the safety and potential acquisition of immunity after vaccination targeting WT1. Further efficacy of WT1-DC vaccine to improve prognosis would be determined by a prospective clinical trial for resectable pancreatic cancer.

摘要

背景/目的：肾母细胞瘤1（WT1）是一种在癌症中高度表达的肿瘤相关抗原。我们研究了WT1肽脉冲树突状细胞（WT1-DC）疫苗联合化疗用于接受手术切除的胰腺癌患者的安全性。